CA2703585A1 - Competitive inhibitors of invariant chain expression and/or ectopic clip binding - Google Patents

Competitive inhibitors of invariant chain expression and/or ectopic clip binding Download PDF

Info

Publication number
CA2703585A1
CA2703585A1 CA2703585A CA2703585A CA2703585A1 CA 2703585 A1 CA2703585 A1 CA 2703585A1 CA 2703585 A CA2703585 A CA 2703585A CA 2703585 A CA2703585 A CA 2703585A CA 2703585 A1 CA2703585 A1 CA 2703585A1
Authority
CA
Canada
Prior art keywords
peptide
clip
binding
score
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2703585A
Other languages
English (en)
French (fr)
Inventor
Martha Karen Newell
Evan Newell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2703585A1 publication Critical patent/CA2703585A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Computing Systems (AREA)
  • Library & Information Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CA2703585A 2007-10-23 2008-10-23 Competitive inhibitors of invariant chain expression and/or ectopic clip binding Abandoned CA2703585A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15207P 2007-10-23 2007-10-23
US61/000,152 2007-10-23
US13715008P 2008-07-25 2008-07-25
US13596408P 2008-07-25 2008-07-25
US61/137,150 2008-07-25
US61/135,964 2008-07-25
PCT/US2008/012078 WO2009055005A2 (en) 2007-10-23 2008-10-23 Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Publications (1)

Publication Number Publication Date
CA2703585A1 true CA2703585A1 (en) 2009-04-30

Family

ID=40580294

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2703585A Abandoned CA2703585A1 (en) 2007-10-23 2008-10-23 Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Country Status (6)

Country Link
US (4) US8957031B2 (https=)
EP (1) EP2215108A4 (https=)
JP (1) JP2011502964A (https=)
AU (1) AU2008317374B2 (https=)
CA (1) CA2703585A1 (https=)
WO (1) WO2009055005A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008211199A1 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
EP2215108A4 (en) * 2007-10-23 2012-07-04 Univ Colorado COMPETITIVE INHIBITORS OF THE EXPRESSION OF THE CONSTANT CHAIN AND / OR THE ECTOPIC CLIP BINDING
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
EP2323679A4 (en) * 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
AU2009274568A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
WO2012094495A2 (en) 2011-01-05 2012-07-12 The Texas A&M University System Clip modulation for the treatment of mucosal diseases
US20140220000A1 (en) * 2011-04-04 2014-08-07 Scott & White Healthcare Mhc engagement and clip modulation for the treatment of disease
WO2013082472A1 (en) 2011-12-01 2013-06-06 The Texas A&M University System Methods and products for treating preeclampsia and modulating blood pressure
WO2015035414A1 (en) * 2013-09-09 2015-03-12 The Texas A&M University System Treating neurological disorders
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
US20170177802A1 (en) * 2015-12-17 2017-06-22 Allergy Solutions, Inc. Allergy Service Management Portal
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
WO2019055860A1 (en) * 2017-09-15 2019-03-21 The Texas A&M University System METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER
US12521201B2 (en) 2017-12-07 2026-01-13 Augmedics Ltd. Spinous process clamp
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
EP3517117A1 (en) * 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A FIDUCIAL MARKER FOR AN AUGMENTED REALITY SYSTEM
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
CN110033822B (zh) * 2019-03-29 2020-12-08 华中科技大学 蛋白质编码方法及蛋白质翻译后修饰位点预测方法及系统
TWI747121B (zh) * 2019-05-21 2021-11-21 大江生醫股份有限公司 茶樹葉的發酵物用於調控ＣＣＴ基因、Ｐｉｎｋ１基因、ＰＡＲＰ２基因、ＭＩＴＦ基因、ＵＮＧ基因、ＥＲＣＣ６基因、ＴＥＲＣ基因、ＣＤ４０基因、ＤＹＮＬＬ２基因、ＧＲＫ５基因、ＲＥＬＢ基因、ＴＮＦＳＦ１４基因、ＩＬ４Ｒ基因與ＲＥＬＡ基因的表現量及抗老化、美白、提升免疫力與降低脂肪累積之用途
CN110296833B (zh) * 2019-07-22 2020-08-18 齐鲁工业大学 一种面向液压缸综合测试台的软测量方法及系统
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
CN116033894A (zh) * 2020-05-22 2023-04-28 卡洛斯·阿尔贝托·里维罗斯 用于减少气道粘膜中的病毒复制的系统、方法和药物使用
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
US12502163B2 (en) 2020-09-09 2025-12-23 Augmedics Ltd. Universal tool adapter for image-guided surgery
US20220293228A1 (en) * 2021-03-09 2022-09-15 Glenn Loomis Identification of Allergens in Food Products
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
US12475662B2 (en) 2021-08-18 2025-11-18 Augmedics Ltd. Stereoscopic display and digital loupe for augmented-reality near-eye display
WO2023203521A1 (en) 2022-04-21 2023-10-26 Augmedics Ltd. Systems and methods for medical image visualization
JP2025531829A (ja) 2022-09-13 2025-09-25 オーグメディックス リミテッド 画像誘導医療介入のための拡張現実アイウェア

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415553A (en) 1973-08-06 1983-11-15 Dso "Pharmachim" Compositions, processes for their preparation and method for treatment of neoplasms
WO1985003003A1 (fr) 1984-01-12 1985-07-18 Volker Rusch Substance biologiquement active avec des proprietes hormonales, son procede de fabrication et utilisation d'histones a des fins medicales
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
WO1993017700A1 (en) 1992-03-13 1993-09-16 Beardsley Terry R Immune-enhancing agent for therapeutic use in immunocompromised hosts
US20050271676A1 (en) 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
EP0728764A4 (en) * 1993-10-19 1999-01-20 Ajinomoto Kk PEPTIDE THE IMMUNE RESPONSE TO HIV UNDUCED AND MEDICINAL PRODUCTS CONTAINING THE PREVENTION OR TREATMENT OF AIDS
US7625565B2 (en) 1995-05-01 2009-12-01 Viral Genetics, Inc. Antiviral compositions comprising lysine-rich histone fractions prepared by pepsin treatment of thymic cell nuclei
WO1996034886A1 (en) 1995-05-01 1996-11-07 Tomson, U.S.A., Ltd. Compositions and methods for detecting and treating acquired immunodeficiency syndrome
AU7690896A (en) 1995-09-14 1997-04-01 Universitat Tubingen Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide
WO1997025344A1 (en) * 1996-01-03 1997-07-17 The Australian National University Clip analogues and autoimmune disease
US20060008448A1 (en) 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
WO1998018491A1 (en) 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
US6326465B1 (en) 1997-02-24 2001-12-04 The Johns Hopkins University Immunomodulatory polypeptides derived from the invariant chain of MHC class II
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6165493A (en) 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
US20020182222A1 (en) 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US20020164685A1 (en) 2000-01-31 2002-11-07 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2004043361A2 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CN1458165A (zh) 2002-01-26 2003-11-26 北海新升技术开发有限责任公司 一种多肽类物质及其制备方法和用途
FR2836483B1 (fr) 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
CN1694696A (zh) 2002-09-23 2005-11-09 牛津大学校委会 亚氨基糖衍生物在抑制离子通道活性中的应用
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2004110349A2 (en) * 2003-05-14 2004-12-23 Siga Technologies, Inc. Sars t cell epitopes and methods for identifying same
EP2292642A1 (en) 2003-06-10 2011-03-09 Opal Therapeutics Pty Ltd Immunomodulating compositions, uses therefor and processes for their production
US7812116B2 (en) 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
US8101714B2 (en) 2004-02-18 2012-01-24 The University Of Georgia Research Foundation, Inc. Teleost derived antimicrobial polypeptides
WO2006114799A1 (en) * 2005-04-27 2006-11-02 Universita' Degli Studi Di Roma 'tor Vergata' Synthetic peptides for the diagnosis and therapy of berillium granulomatous disease
US20080094510A1 (en) * 2005-08-05 2008-04-24 Samsung Electronics Co., Ltd. Apparatus for providing multiple screens and method of dynamically configuring multiple screens
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
US20080095798A1 (en) 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
US20090291884A1 (en) 2006-11-02 2009-11-26 Michael Agadjanyan Proteins for use in diagnosing and treating infection and disease
AU2008211199A1 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
EP2215108A4 (en) 2007-10-23 2012-07-04 Univ Colorado COMPETITIVE INHIBITORS OF THE EXPRESSION OF THE CONSTANT CHAIN AND / OR THE ECTOPIC CLIP BINDING
WO2010008554A2 (en) * 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
AU2009274568A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
WO2010011343A2 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
WO2012094495A2 (en) 2011-01-05 2012-07-12 The Texas A&M University System Clip modulation for the treatment of mucosal diseases
US20140220000A1 (en) * 2011-04-04 2014-08-07 Scott & White Healthcare Mhc engagement and clip modulation for the treatment of disease
WO2013082472A1 (en) * 2011-12-01 2013-06-06 The Texas A&M University System Methods and products for treating preeclampsia and modulating blood pressure

Also Published As

Publication number Publication date
US20110118175A1 (en) 2011-05-19
WO2009055005A9 (en) 2009-09-24
US20200069766A1 (en) 2020-03-05
AU2008317374A1 (en) 2009-04-30
EP2215108A4 (en) 2012-07-04
US10420813B2 (en) 2019-09-24
US8957031B2 (en) 2015-02-17
EP2215108A2 (en) 2010-08-11
AU2008317374B2 (en) 2015-03-19
JP2011502964A (ja) 2011-01-27
WO2009055005A3 (en) 2009-08-13
US20170348377A1 (en) 2017-12-07
WO2009055005A2 (en) 2009-04-30
US20150231195A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
US10420813B2 (en) Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US20100166789A1 (en) Proteins for use in diagnosing and treating infection and disease
US20130259829A1 (en) Clip inhibitors and methods of modulating immune function
US20100034839A1 (en) Methods for treating viral disorders
Phan et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells
JP2021178854A (ja) がんの処置および予防のためのワクチン
US10011602B2 (en) Immunological reagents and uses therefor
EP2633864A1 (en) Clip inhibitors and methods of modulating immune function
JP2018065834A (ja) 高コレステロール血症、アテローム性動脈硬化症、冠動脈性心疾患、胆石、肥満症、および他の心血管疾患の処置のために有用なグアニル酸シクラーゼのアゴニスト
Machado et al. Homology modeling, vasorelaxant and bradykinin-potentiating activities of a novel hypotensin found in the scorpion venom from Tityus stigmurus
US20140220000A1 (en) Mhc engagement and clip modulation for the treatment of disease
WO2021113311A9 (en) Treatment of cancer using acetylcholine modulation and immunotherapy
Liu et al. Identification of small-molecule inhibitors against human leukocyte antigen-death receptor 4 (HLA-DR4) through a comprehensive strategy
US20170360875A1 (en) Methods for treating immune-mediated viral infections
EP4306125A1 (en) Immunogenic personalised cancer vaccines
Sussman Belimumab and Rituximab Efficacy and Safety in Patients with Systemic Lupus Erythematosus with and without Renal Involvement
Zavala-Ruiz Structure studies of the human class II major histocompatibility complex protein HLA-DR1
Natarajan et al. The Peptide-Receptive Transition State of

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131023

FZDE Discontinued

Effective date: 20230425